No Data
No Data
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
Express News | TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Sage Raised to Sector Perform by RBC in Wake of Drug Failure
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14